INTRODUCTION
============

More than 90% of adults worldwide are infected with *Epstein-Barr virus* (EBV) and they carry the virus as a life-long persistent infection, with latent infection of their B lymphocytes and viral production into their saliva[@B1], [@B2]. EBV is associated with the pathogenesis of several different types of aggressive non-Hodgkin\'s lymphoma (NHL) and Hodgkin\'s lymphoma. In 1976, screening 27 cases of lymphoid tissue lesions for EBV-DNA with using nucleic acid reassociation kinetics led to the detection of one virus-positive case of angioimmunoblastic T-cell lymphoma (AILT)[@B3]. Many subsequent studies have demonstrated the presence of EBV in 58\~97% of all AILT cases in either the T or B cells[@B4]-[@B7]. The clinical presentation of AILT is usually systemic disease with B symptoms, while the pathology reveals a polymorphous infiltrate involving the lymph nodes with a prominent proliferation of endothelial and dendritic cells[@B8]. Some patients go on to develop a secondary EBV-positive large B-cell lymphoma.

A recent study demonstrated that the presence of EBV-DNA obtained by performing real-time quantitative PCR and Southern blotting analysis of tumor tissue had no significant effect on the clinical outcome of AILT patients[@B9]. As for the patients with nasal NK/T-cell lymphoma, a EBV-positive tumor is a prerequisite for making the diagnosis[@B10]. A recent study proved that minimal EBV involvement in the bone marrow (BM) was a powerful prognostic marker[@B11].

Therefore, we performed this study to evaluate the rate of EBV-positivity in tumor and BM and their prognostic values for the clinical outcome of AILT patients.

MATERIALS AND METHODS
=====================

Patients
--------

Over a period of 8 years (from August 1998 to July 2005), 70 AILT cases from 8 medical centers were identified based on the histological and immunohistochemical criteria with using the REAL and/or WHO classifications. We enrolled 27 patients who had additional tissue slides for EBV *in situ hybridization* (ISH). Ten patients\' BM slides were also analyzed in this study. Eight patients had their cryopreserved BM mononuclear cells for performing EBV DNA PCR.

All the patients were staged according to the Ann Arbor staging system. The complete staging procedures included physical examination, chest X-ray, complete blood cell counts, blood biochemistry, computed tomography of the thorax, abdomen and pelvis, and BM aspiration and biopsy. The clinical and laboratory records were reviewed for all the patients.

Treatment
---------

The chemotherapy regimens included CHOP (cyclophosphamide, Hydroxydaunomycin, vincristin and prednisone), CHOP-E (etoposide) or ESHAP (etoposide, solumedrol, cytarabine and cisplatin).

ISH for EBV in the tumor and BM biopsy[@B12]
--------------------------------------------

We performed EBV ISH on 27 tumor specimens and 10 BM biopsy specimens. The paraffin-embedded sections of the biopsy specimens were deparaffinized with xylene, and this was followed by treatment with proteinase K. The sections were then hybridized with fluorescein isothiocynanate-conjugeted EBV oligonucleotides (Novocastra, Newcastle, U.K.) that were complementary to the nuclear RNA protein of the EBER1 and EBER2 genes. Positive labeling was identified only when the cells showed nuclear staining with EBV oligonucleotide. As negative controls, we used EBV negative lymphoid tissues and a hybridization mixture without the EBV oligonucleotides. As the internal positive control, the tumor and BM slides of patient with NK-cell leukemia were used.

Sample DNA preparation and EBV PCR[@B11]
----------------------------------------

The BM mononuclear cells from 8 patients were studied by performing EBV PCR. EBV DNA was extracted from the patients\' BM aspiration samples (frozen monocytes) with using the QIAmp DNA Blood Mini Kit (Qiagen, USA). Approximately 100ng of DNA was used for PCR reaction. The PCR primer sequences were 5\'-GACGAGGGGCCAGGTACAGG-3\' and 3\'-GCAGCCAATGCAACTTGGACGTTTTAGG-5\', respectively. The PCR reaction was performed using the primer set (Maxim biotech, Inc, USA). The PCR mixture contained 250 µL of the pre-mixed primers and 750 µL of optimized PCR buffer. The PCR was preformed in a total volume of 50 µL, which contained 10.0 L of DNA, 39.8 L of the PCR mixture and 0.2 µL of Taq DNA polymerase. The amplification reaction was performed for 37 cycles under the following conditions: initially, 96℃ for 1min for activation (one cycle), followed by a denaturation phase at 94℃ for 1min, an annealing phase at 5 8℃ for 1min and an extension phase at 72℃ for 1min (35 cycles). Another 10 min extension phase at 72℃ was performed at the end of each round of PCR. Ten microliters of the PCR products were subjected to electrophoresis (100V, 25min) on a 2% agarose gel, and the products were stained with ethidium bromide. The presence or absence of specific PCR targets was observed under UV illumination.

Statistical analysis
--------------------

Overall survival was measured from the time of diagnosis to death or to the last follow-up. The survival curves were calculated using the Kaplan-Meier method and they were then compared using the log-rank test. Other clinical factors were compared using chi-square tests or *t*-tests. Differences were considered statistically significant if the *p* value was \<0.05. All statistical analyses were performed using the SPSS for Windows 13.0 statistical package (SPSS Inc., Chicago, IL).

RESULTS
=======

Clinical features
-----------------

One patient among the 27 AILT patients refused any further staging work-up. The clinicopathologic data of the 27 patients are summarized in [Table 1](#T1){ref-type="table"}. This series included 19 men and 8 women with ages from 17 to 75 (median age: 57 years-old). All the patients except one had stage III or IV disease. Anemia was detected at diagnosis in 10 patients; two of them had autoimmune hemolytic anemia. Twenty five patients received chemotherapy, including 23 patients who received CHOP, 1 patient who received CHOP-E and 1 patient who received ESHAP, while 2 patients received only supportive care.

EBV ISH in the tumor and its clinical impact
--------------------------------------------

Among the tumor specimens obtained at the time of the initial diagnosis from the 27 AILT patients, 10 were positive for EBV ISH. The correlations of the clinical status, such as the international prognostic index (IPI) score, age, stage and other laboratory findings, with the EBV status of tumor are summarized in [Table 2](#T2){ref-type="table"}. Only CD20 negativity in the tumor was significant correlated with EBV-positivity in the tumor (*p*=0.035).

The median overall survival and progression-free survival of the 25 treated patients were 48.9 months (95% CI: 18.6\~79.2 months) and 32.3 months (95% CI: 11.5\~53.1 months) ([Figure 1A](#F1){ref-type="fig"}). There were no significant correlations between EBV-positivity in tumor and the overall or progression-free survival.

BM involvement by Hematoxylin-eosin staining, ISH or PCR
--------------------------------------------------------

In 13 of the 26 AILT patients, gross tumor involvement was recognized in the initial BM sample by hematoxylin-eosin staining (H-E stain). None of the 10 patients who had additional BM slides available revealed EBV-positivity on BM ISH. Among these 10 patients, 3 patients showed BM involvement by H-E staining, but this was not identified on EBV ISH ([Figure 2](#F2){ref-type="fig"}) or PCR. Yet one patient among the 5 patients without BM involvement showed a positive band on PCR ([Figure 3](#F3){ref-type="fig"}). BM involvement by H-E staining was not related with the clinical status as defined by the IPI, age, stage and laboratory findings ([Table 3](#T3){ref-type="table"}). The overall survival and progression-free survival for the treated patients among the 13 patients with BM involvement according to H-E staining, were longer than those for the patients without BM involvement (*p*=0.054 and *p*=0.005, respectively; [Figure 1B, 1C](#F1){ref-type="fig"}).

Clinical factors affecting survivals
------------------------------------

On univariate analysis, older age, male gender, pulmonary parenchymal involvement, the presence of edema and negative BM were adverse factors for progression-free survival and overall survival. Male gender (*p*=0.041), pulmonary parenchymal involvement (*p*=0.039) and negative BM (*p*=0.042) all significantly shortened the progression-free survival on multivariate analysis. Among the significant factors for overall survival, male gender (*p*=0.078), pulmonary parenchymal involvement (*p*=0.044) and negative BM (*p*=0.080) also had modest significance on multivariate analysis.

DISCUSSION
==========

EBV DNA was detected in Burkitt\'s lymphoma tissue in 1964, from non-Hodgkin\'s lymphoma in the early 1980s and from T-cell lymphoma and Hodgkin\'s lymphoma in the late 1980s[@B13]. Clonotypic proliferation of EBV has been demonstrated in the neoplastic cells of lymphoid malignancies, which suggests a causative role for EBV in their tumorigenesis[@B14]. The cells infected with EBV are thought to avoid apoptosis by expressing EBV latent membrane proteins (LMP) 1 (CD 40 homologue) and 2a (BCR engagement). Infected B cells are delivered by binding to helper T cells via the CD40 molecule that presents on the B cell surface, and by binding to the B cell receptor[@B1]. The outcome of AILT is poor, with most series reporting a 5-year OS of approximately 30% and a median survival of 3 years[@B15]. Several studies have been done to assess how the pathogenesis of EBV contributes to the prognosis. Anagonostopoulos et al[@B7] showed the predominant infection of B cells in the nodular EBV-positive cases and the predominant infection of T cells in the diffusely EBV-positive cases, and this was confirmed by double labeling for EBER and the lineage markers for all the AILT cases. Further, EBV infection of the two cell lineages would appear to be unique to AILT as this has not yet been reported for other malignancies, but the pathway of B- and T-cell infection by EBV in AILT patients is unclear. Our study showed that CD20 negativity of a tumor was significant correlated with EBV ISH positivity (*p*=0.035).The expression of the CD20 antigen may be down regulated in latently EBV-infected small lymphoid cells in vivo[@B16]. Our findings supported this observation. Several other articles showed the contradictory result that AILT often have increased numbers of CD20-positive cells that are also EBV-positive[@B17]-[@B19]. This discrepancy needs further verification. The relative lower incidence (37%) of EBV-positivity of tumor in this study was lower when compared to that (58\~97%) of western studies. We used an adequate positive control, that is, EBV-positive NK/T-cell leukemia. Therefore, using more sensitive methods such as PCR to detect low copy numbers of EBV would be the next step[@B9], [@B20].

Another aim of this study was to adopt the prognostic model of minimal BM involvement by EBV-positive tumor cells in NK/T-cell lymphoma and apply it to AILT. Unexpectedly, it was difficult to use EBV ISH or PCR for detecting EBV-positive tumor cells in BM, such as those EBV-positive tumor cells in NK/T-cell lymphoma. The EBV ISH or PCR results were all negative for the AILT patients with gross tumor involvement, as determined by H-E staining. This made it impossible to introduce the concept of minimal BM involvement by EBV-positive tumor cells in AILT. Also, the results of performing EBV ISH and/or PCR for tumor or BM had no impact on the outcomes of the AILT patients in our study; this was similar to a recent Japanese study[@B9].

Our study showed a particular result that the overall survival and progression free survival of the AITL patients with BM involvement were significant longer than those of the patients without BM involvement. Of course, the limited number of patients makes it difficult to generalize this finding. However, most AILT patients in this study were at an advanced stage of disease at the time of diagnosis. Except for stage, patient survival was significantly related to age, B cell symptoms, rash/pruritus, edema, ascites, lactate dehydrogenase, hemoglobin and the number of clinical symptoms with excluding the B symptoms of the AILT patients[@B21]. The presence of bulky disease (\>7.5 cm), an advanced stage and bone marrow involvement did not influence survival of the patients with T-cell lymphoma in the previous studies[@B22], [@B23]. Unlike B-cell lymphoid malignancies such as diffuse large B-cell lymphoma and chronic lymphoid leukemia, BM involvement may not be a poor prognostic factor for T-cell lymphoma. A future study that would include a sufficient number of AILT patients will clarify this particular finding.
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![In situ hybridization for EBV in the bone marrow biopsies. Positive staining for EBV in a case with NK/T-cell leukemia (A), and negative staining in a patient with angioimmunoblastic T-cell lymphoma (B)](kjim-23-30-g002){#F2}
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Clinicopathologic findings of the 27 patients with angioimmunoblastic T-cell lymphoma
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NE, not evaluated; A, alive; D, death.
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Correlation between tumor EBV positivity on ISH and the clinico-laboratory findings
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Correlation between BM involvement and the clinicolaboratory findings
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